Martin Marietta Materials Inc
Change company Symbol lookup
Select an option...
MLM Martin Marietta Materials Inc
KO Coca-Cola Co
VICI VICI Properties Inc
PLT Plantronics Inc
THG Hanover Insurance Group Inc
USB U.S. Bancorp
BAC Bank of America Corp
TCNNF Trulieve Cannabis Corp
RM Regional Management Corp
KTOS Kratos Defense and Security Solutions Inc

Materials : Construction Materials | Mid Cap Blend
Company profile

Martin Marietta Materials, Inc. is a supplier of aggregates products (crushed stone, sand, and gravel) used for the construction of infrastructure, nonresidential, and residential projects. Aggregates products are also used for railroad ballast and in agricultural, utility and environmental applications. The Company's Aggregates business operates through three segments: the Mid-America Group, Southeast Group and West Group. The Company's business is categorized into Aggregates Business, Cement Business and Magnesia Specialties Business. Its Cement business is reported through the Cement segment. Its Magnesia Specialties business manufactures and markets magnesia-based chemical products used in industrial, agricultural, and environmental applications, and dolomitic lime sold to customers in the steel industry. Its Cement business produces Portland and specialty cements. It manufactures and markets, through its Magnesia Specialties business, magnesia-based chemical products.

Day's Change
-0.045 (-0.02%)
B/A Size
Day's High
Day's Low

Today's volume of 413,230 shares is on pace to be in-line with MLM's 10-day average volume of 473,104 shares.


Gilead's remdesivir improves time to recovery for COVID-19 patients in peer-reviewed results, NIAID says

7:15 pm ET May 22, 2020 (MarketWatch)

Gilead Sciences Inc.'s antiviral drug remdesivir improved COVID-19 patients' recovery time in peer-reviewed data from a study by the National Institute of Allergy and Infectious Diseases, the NIAID announced Friday afternoon. In a follow-up to positive preliminary data released last month (, NIAID revealed Friday that peer-reviewed data showed that patients recovered enough to be released from the hospital in 11 days against 14 for those who received a placebo. It also noted that the 14-day mortality rate for those on the drug declined to 7.1% from 11.9% for the placebo group, though NIAID is still investigating combinations that could produce a more statistically significant change -- a clinical trial that began May 8 is studying remdesivir in combination with anti-inflammatory drug baricitinib to study those results. The Food and Drug Administration has granted Gilead emergency-use authorization for the drug ( to use on severely ill COVID-19 patients, and Gilead has signed deals for manufacturing ( Gilead stock was 0.4% lower in after-hours trading Friday following the announcement; shares have gained 12.9% so far this year, as the S&P 500 index has declined 8.5%.

-Jeremy C. Owens; 415-439-6400;

(END) Dow Jones Newswires

May 22, 2020 19:15 ET (23:15 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.